Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin

References

• IssaMMFenterTCBlackLGroggALKruepEJAn assessment of the diagnosed prevalence of diseases in men 50 years of age or olderAm J Manag Care200612S83S8916551206
   PubMed Web of Science ®Google Scholar
• NaslundMJIssaMMGroggALEaddyMTBlackLClinical and economic outcomes in patients treated for enlarged prostateAm J Manag Care200612S111S11616551204
   PubMed Web of Science ®Google Scholar
• GravasSMelekosMDMale lower urinary tract symptoms: How do symptoms guide our choice of treatment?Curr Opin Urol200919495419057216
   PubMed Web of Science ®Google Scholar
• BarkinJRoehrbornCGSiamiPEffect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trialBJU Int200910391992619239460
   PubMed Web of Science ®Google Scholar
• BarryMJO’LearyMPAdvances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scoresUrol Clin North Am1995222993077539176
   PubMed Web of Science ®Google Scholar
• ChappleCRRoehrbornCGA shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladderEur Urol20064965165816530611
   PubMed Web of Science ®Google Scholar
• AbramsPChappleCKhourySRoehrbornCde la RosetteJEvaluation and treatment of lower urinary tract symptoms in older menJ Urol20091811779178719233402
   PubMed Web of Science ®Google Scholar
• American Urological Association Education Research IChapter 1. AUA guideline on the management of benign prostatic hyperplasia: Diagnosis and treatment recommendations Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/bph-management/preface_toc.pdf. Accessed March 9, 2011.
   Google Scholar
• MehdizadehJLLeachGERole of invasive urodynamic testing in benign prostatic hyperplasia and male lower urinary tract symptomsUrol Clin North Am20093643144119942043
   PubMed Web of Science ®Google Scholar
• RoehrbornCGClinical management of lower urinary tract symptoms with combined medical therapyBJU Int2008102Suppl 2131719032605
   PubMed Web of Science ®Google Scholar
• MadersbacherSMarbergerMIs transurethral resection of the prostate still justified?BJU Int19998322723710233485
   PubMed Web of Science ®Google Scholar
• ReichOGratzkeCBachmannAMorbidity, mortality and early outcome of transurethral resection of the prostate: A prospective multicenter evaluation of 10,654 patientsJ Urol200818024624918499179
   PubMed Web of Science ®Google Scholar
• BurkeNWhelanJPGoereeLSystematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstructionUrology2010751015102219854492
   PubMed Web of Science ®Google Scholar
• AhyaiSAGillingPKaplanSAMeta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargementEur Urol20105838439720825758
   PubMed Web of Science ®Google Scholar
• NaslundMEaddyMTHogueSLKruepEJShahMBImpact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: Assessment of acute urinary retention and prostate-related surgeryCurr Med Res Opin2009252663266919757985
   PubMed Web of Science ®Google Scholar
• BarendrechtMMAbramsPSchumacherHde la RosetteJJMichelMCDo alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?Neurourol Urodyn20082722623017638312
   PubMed Web of Science ®Google Scholar
• OelkeMBachmannADescazeaudAConservative treatment of non-neurogenic male LUTS Available at: http://www.uroweb.org/?id=217&tyid=2. Accessed March 1, 2011.
   Google Scholar
• CantrellMABream-RouwenhorstHRHemersonPMageraJSJrSilodosin for benign prostatic hyperplasiaAnn Pharmacother20104430231020071497
   PubMed Web of Science ®Google Scholar
• GarimellaPSFinkHAMacdonaldRWiltTJNaftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasiaCochrane Database Syst Rev2009CD00736019821408
   PubMed Web of Science ®Google Scholar
• MichelMCKorstanjeCKrauwinkelWKuipersMThe pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®)Eur Urol Suppl200541524
   Web of Science ®Google Scholar
• KeamSJScottLJDutasteride: A review of its use in the management of prostate disordersDrugs20086846348518318566
   PubMed Web of Science ®Google Scholar
• RittmasterRSNormanRWThomasLNRowdenGEvidence for atrophy and apoptosis in the prostates of men given finasterideJ Clin Endocrinol Metab1996818148198636309
   PubMed Web of Science ®Google Scholar
• DjavanBHandlMJDianatSCombined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasiaExpert Opin Pharmacother2010112535254720854184
   PubMed Web of Science ®Google Scholar
• WangCPhosphodiesterase-5 inhibitors and benign prostatic hyperplasiaCurr Opin Urol201020495419887943
   PubMed Web of Science ®Google Scholar
• DjavanBMargreiterMDianatSSAn algorithm for medical management in male lower urinary tract symptomsCurr Opin Urol20112151221045704
   PubMed Web of Science ®Google Scholar
• IrwinDEMilsomIHunskaarSPopulation-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC studyEur Urol2006501306131417049716
   PubMed Web of Science ®Google Scholar
• Abdel-AzizKFLemackGEOveractive bladder in the male patient: Bladder, outlet, or both?Curr Urol Rep2002344545112425865
   PubMedGoogle Scholar
• CambioAJEvansCPOutcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Ther Clin Risk Manag2007318119618360626
   PubMedGoogle Scholar
• BarryMJFowlerFJJrO’LearyMPThe American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological AssociationJ Urol1992148154915571279218
   PubMed Web of Science ®Google Scholar
• MacDonaldDMcNicholasTADrug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: Focus on quality of lifeDrugs2003631947196212930164
   PubMed Web of Science ®Google Scholar
• BarryMJFowlerFJJrO’LearyMPBruskewitzRCHoltgreweHLMebustWKCorrelation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological AssociationJ Urol1992148155815631279219
   PubMed Web of Science ®Google Scholar
• BarryMJFowlerFJJrO’LearyMPBruskewitzRCHoltgreweHLMebustWKMeasuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological AssociationMed Care199533AS145AS1557536866
   PubMed Web of Science ®Google Scholar
• AngalakuditiMSeifertRFHayesRPO’LearyMPViktrupLMeasurement properties of the benign prostatic hyperplasia impact index in tadalafil studiesHealth Qual Life Outcomes2010813121073697
   PubMed Web of Science ®Google Scholar
• Marklund-BauHEdell-GustafssonUSpangbergABothersome urinary symptoms and disease-specific quality of life in patients with benign prostatic obstructionScand J Urol Nephrol200741324117366100
   PubMed Web of Science ®Google Scholar
• BarryMJWillifordWOChangYBenign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?J Urol1995154177017747563343
   PubMed Web of Science ®Google Scholar
• BlackLGroveAMorrillBThe psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptomsHealth Qual Life Outcomes200975519545384
   PubMed Web of Science ®Google Scholar
• KirbyRSRoehrbornCBoylePEfficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trialUrology20036111912612559281
   PubMed Web of Science ®Google Scholar
• McConnellJDRoehrbornCGBautistaOMThe long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med20033492387239814681504
   PubMed Web of Science ®Google Scholar
• BecherERoehrbornCGSiamiPGagnierRPWilsonTHMontorsiFThe effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin studyProstate Cancer Prostatic Dis20091236937419901936
   PubMed Web of Science ®Google Scholar
• RoehrbornCGSiamiPBarkinJThe effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyEur Urol20105712313119825505
   PubMed Web of Science ®Google Scholar
• MontorsiFHenkelTGeboersAEffect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT studyInt J Clin Pract2010641042105120487046
   PubMed Web of Science ®Google Scholar
• FenterTCRunkenMCBlackLEaddyMFinasteride versus dutasteride: A real-world economic evaluationAm J Manag Care200713Suppl 1S23S2817295602
   PubMed Web of Science ®Google Scholar
• NaslundMBlackLEaddyMBatisteLRDifferences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIsAm J Manag Care200713Suppl 1S17S2217295601
   PubMed Web of Science ®Google Scholar
• EmbertonMMedical treatment of benign prostatic hyperplasia: Physician and patient preferences and satisfactionInt J Clin Pract2010641425143520579137
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineThe first fixed dose combination medicine for benign prostatic hyperplasia Available at: http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10036.htm. Accessed March 9, 2011.
   Google Scholar
• GlaxoSmithKlineFDA approves Jalyn™, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate Available at: http://www.gsk.com/media/pressreleases/2010/2010_us_pressrelease_10035.htm. Accessed March 9, 2011.
   Google Scholar
• LeporHWillifordWOBarryMJThe efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study GroupN Engl J Med19963355335398684407
   PubMed Web of Science ®Google Scholar
• DebruyneFMJardinAColloiDSustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study GroupEur Urol1998341691759732187
   PubMed Web of Science ®Google Scholar
• KirbyRSA randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasiaBJU Int200391414412614248
   PubMed Web of Science ®Google Scholar
• RoehrbornCGSiamiPBarkinJThe effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT studyJ Urol200817961662118082216
   PubMed Web of Science ®Google Scholar